A Blueprint for Breakthrough – Charting the Course for Precision Medicine

September 13, 2017
Marriott Marquis Hotel

901 Massachusetts Ave NW, Washington, DC 20001

Thank you to all that attended. To access a full recap, including links to relevant papers, videos, and presentations, Click HERE.

Join us on September 13, 2017, as Friends of Cancer Research and Alexandria Real Estate Equities Inc. host this year’s Blueprint for Breakthroughs. This year’s event will focus on the course ahead for precision medicine and will include a morning keynote address and two panel discussions.

Please find this year’s agenda below.

8:00 AM – Registration and Breakfast

8:30 AM – Welcome Remarks

Ellen Sigal, Friends of Cancer Research
Lynne Zydowsky, Alexandria Real Estate Equities, Inc.

8:40 AM – Morning Keynote Address

Scott Gottlieb, Commissioner, U.S. FDA

9:00AM – Regulatory Landscape for Precision Medicine

Adam Berger, U.S. FDA

9:15AM – Current State of Precision Medicine Development

Julie Dixon, Bristol-Myers Squibb

Panel 1 Discussion: Establishing Analytical Standards and Identifying Critical Performance Characteristics

Moderator: Mya Thomae, Regulatory Advisor

Dara Aisner, University of Colorado Denver
Rasika Kalamegham, Genentech
Lisa McShane, NCI
Jason Merker, Stanford University
Reena Philip, U.S. FDA
Erasmus Schneider, NY State Department of Health

Panel 2 Discussion: Streamlining Modifications to Diagnostic Tests

Moderator: Elizabeth Mansfield, GRAIL

Gideon Blumenthal, U.S. FDA
Keith Flaherty, Massachusetts General Hospital
David Kaufman, Merck
David Litwack, U.S. FDA
Kelli Tanzella, Thermo Fisher Scientific

Panel 3 Discussion: Driving Uptake of High Quality Precision Medicine Tools

Moderator: Kate Rawson, Prevision Policy

Joseph Chin, CMS
Andrea Ferris, Lungevity
Zach Hornby, Ignyta
John Iafrate, Massachusetts General Hospital
Michael Pellini, Foundation Medicine
Jeffrey Shuren, U.S. FDA